Davis ID - Search Results

1

Targeted therapies in the treatment of renal cell carcinoma.

Pezaro C, Davis ID. Pezaro C, et al. Among authors: davis id. Curr Med Chem. 2008;15(12):1166-74. doi: 10.2174/092986708784310440. Curr Med Chem. 2008. PMID: 18473811 Review.

2

Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.

Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM. Ramdave S, et al. J Urol. 2001 Sep;166(3):825-30. J Urol. 2001. PMID: 11490227

3

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM. Davis ID, et al. Cancer Immun. 2007 Aug 17;7:13. Cancer Immun. 2007. PMID: 17705349 Free PMC article. Clinical Trial.

4

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Grossmann M, Premaratne E, Desai J, Davis ID. Grossmann M, et al. Among authors: davis id. Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x. Epub 2008 Apr 3. Clin Endocrinol (Oxf). 2008. PMID: 18394019

5

Clinical use of therapies targeting tumor vasculature and stroma.

Davis ID, Desai J. Davis ID, et al. Curr Cancer Drug Targets. 2008 Sep;8(6):498-508. doi: 10.2174/156800908785699388. Curr Cancer Drug Targets. 2008. PMID: 18781896 Review.

6

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC. Pezaro C, et al. Among authors: davis id. Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b. Am J Clin Oncol. 2009. PMID: 19363437 Clinical Trial.

7

Urothelial cancers: using biology to improve outcomes.

Pezaro C, Liew MS, Davis ID. Pezaro C, et al. Among authors: davis id. Expert Rev Anticancer Ther. 2012 Jan;12(1):87-98. doi: 10.1586/era.11.195. Expert Rev Anticancer Ther. 2012. PMID: 22149435 Review.

8

Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.

Tafreshi A, Thientosapol E, Liew MS, Guo Y, Quaggiotto M, Boyer M, Davis ID. Tafreshi A, et al. Among authors: davis id. Asia Pac J Clin Oncol. 2014 Mar;10(1):60-5. doi: 10.1111/ajco.12122. Epub 2013 Oct 24. Asia Pac J Clin Oncol. 2014. PMID: 24152417 Clinical Trial.

9

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Motzer RJ, et al. Among authors: davis id. Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17. Lancet Oncol. 2014. PMID: 24556040 Free PMC article. Clinical Trial.

10

Prostate cancer: measuring PSA.

Pezaro C, Woo HH, Davis ID. Pezaro C, et al. Among authors: davis id. Intern Med J. 2014 May;44(5):433-40. doi: 10.1111/imj.12407. Intern Med J. 2014. PMID: 24816306 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

308 results

Search Page